Patent classifications
G01N2030/067
Allergen detection method
A highly-sensitive-allergen-measurement method is provided. A method for detecting an allergen in a sample comprises treating the sample with a protease, and detecting the presence or absence of an allergen-derived polypeptide in the enzymatically treated sample by a chromatographic separation analysis, wherein the allergen is one or more members selected from the group consisting of buckwheat, crustacean, milk, egg and peanut.
SYSTEM AND METHOD FOR ANALYSING THE COMPOSITION OF A QUENCHED FLOW REACTION LIQUID
The present invention relates to a system for analysing the composition of a quenched flow reaction liquid comprising a quenched flow reactor, and a high performance liquid chromatography (HPLC) apparatus; wherein the quenched flow reactor is in fluid communication with the HPLC apparatus.
METHOD OF EVALUATING DEGREE OF PURITY OF PHARMACEUTICAL SUBSTANCE CONTAINED IN COMPOSITE BODY, AND METHOD OF PRODUCING COMPOSITE BODY
A method enables evaluation of the purity of an active pharmaceutical ingredient contained in a complex, and a method of producing a complex in which the purity of the active pharmaceutical ingredient is not less than 95.0%. The purity evaluation method includes: a reaction step of reacting a complex with a nitrogen-containing nucleophile such as hydroxylamine in the presence of a protonic acid in a polar solvent; and an evaluation step of evaluating the purity of the reaction mixture obtained by the reaction step, by high-performance liquid chromatography. The method of producing a complex includes a reaction step of reacting an anthracycline drug with an N-(2-hydroxypropyl)methacrylamide polymer in the presence of a protonic acid in a polar solvent at not more than 10° C., to obtain the complex.
Sample preparation for proteomic investigations
A method for disrupting a sample of biological material of human, animal, or plant origin for subsequent proteome analysis by a mass spectrometry method is provided. The method involves disrupting the sample by treatment with a certain volume of an organic acid until the sample completely dissolves, incubating the sample for a certain period, and then neutralizing the sample with a neutralizing solution until a pH value between 7 and 9 is reached.
AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS
Described herein are the amphetamine-related compounds amphetamine carbamate (amphetammonium-amphetacarbamate) and amphetacarbamate, methods of making them, methods for detecting or quantitatively determining the amount of amphetacarbamate or amphetamine carbamate in a compositions, and ion chromatography columns useful in such methods.
MONITORING ANALYSIS DEVICE AND MONITORING ANALYSIS METHOD
A monitoring analysis device includes an acquirer that sequentially acquires reaction products produced by a reactor, an analyzer that sequentially analyzes the reaction products acquired by the acquirer, a pre-processor that performs a pre-process to be performed before an analysis of the reaction products by the analyzer, and a controller that controls the pre-processor such that the pre-process for a second analysis to be performed subsequently to a first analysis is performed during the first analysis by the analyzer.
METHOD OF PROCESSING A BIOLOGICAL SAMPLE
A method of processing of a biological sample containing multiple metabolites is described The method comprising the steps of pre-treating the biological sample with a metabolite extraction solvent to provide a pre-treated sample, separating a first aliquot of the pre-treated sample by reverse phase liquid chromatography (RPLC) to provide a first eluent containing resolved hydrophobic metabolites, and separating a second aliquot of the pre-treated sample by hydrophilic interaction liquid interaction chromatography (HILIC) to provide a second eluent containing resolved hydrophilic metabolites. The first and second eluents are assayed using targeted tandem mass spectroscopy operated in multiple reaction monitoring mode. Each liquid chromatography step(LC) is directly hyphenated with the tandem mass spectrometry (MS/MS) into a single LC-MS/MS analysis. The extraction solvent typically comprises methanol, isopropanol and an acetate buffer.
METHOD OF USING CHEMICAL TAGS TO IMPROVE THE IDENTIFICATION, QUANTIFICATION AND SPATIAL LOCALIZATION OF COMPONENTS IN A SAMPLE
The present disclosure relates to a method for using chemical tags which have two or more sites for ionization to improve quantification and identification of components of interest from a complex mixture. This method relies on first selectively reacting one or more component in a sample with a chemical tag having two or more sites for ionization, followed by separation of components based on charge status, and finally characterization of each component to identify the same. Additionally disclosed are compounds useful as chemical tags in the disclosed methods.
Method for simultaneous determination of nitrogen and oxygen isotope compositions of natural nitrate and nitrite
A method for simultaneous determination of nitrogen and oxygen isotope compositions of natural nitrate and nitrite, which quantitatively converts natural nitrate and nitrite into an organic ester and a nitro-compounds respectively, and then nitrate and nitrite δ.sup.18O and δ.sup.15N are simultaneously determined by adopting a gas chromatography/pyrolysis/gas chromatography/isotope ratio mass spectrometry coupling technology (GC/Py/GC/IRMS). According to the method for simultaneously determining the nitrogen and oxygen isotope compositions of the natural nitrate salt and nitrite salt, the small amount of sample does not result in the loss, acquisition, exchange and fractionation of nitrogen and oxygen.
ANALYSIS METHOD OF 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT, TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS, INHIBITION OF PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS, AND METHOD OF PRODUCING MEDICAMENT CONTAINING 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT
A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 μg/mL to 10 μg/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value. The first acidic water includes hydrochloric acid, the first water-soluble organic solvent is acetonitrile and/or methanol, the second acidic water includes hydrochloric acid, and the second water-soluble organic solvent is acetonitrile and/or methanol.